Table 1 Demographic Clinical Characteristics of the Patients.
No high risk Cytogenetic abnormality (n = 126) | One high Risk Cytogenetic Abnormality (n = 24) | Two High Risk Cytogenetic Abnormalities (n = 7) | Three High Risk Cytogenetic Abnormalities (n = 2) | Total (n = 159) | |
|---|---|---|---|---|---|
Demographic and Clinical Characteristics of the Patients | |||||
Age (years) | 64.5 ± 11.5 | 65.4 ± 9.4 | 61.6 ± 9.9 | 71.0 ± 4.2 | 64.6 ± 11.1 |
Gender (male/female) | 60/66 | 12/12 | 2/5 | 2/0 | 76/83 |
ISS stage at diagnosis | |||||
Stage 1 | 70 (%58.8) | 1 (%4.3) | 0 | 0 | 71(%47.0) |
Stage 2 | 44 (%37.0) | 9 (%34.8) | 1 (%14.3) | 0 | 53(%35.1) |
Stage 3 | 5 (%4.2) | 14 (%60.9) | 6 (%85.7) | 2 (%100.0) | 27(%17.9 |
First Line Treatment | |||||
VCD | 75 (%59.5) | 14(%58.3) | 7 (%100.0) | 2(%100.0) | 98(%61.6) |
VD | 25 (%19.8) | 3 (%12.5) | 0 | 0 | 28(%17.6) |
VTD-PACE | 0 | 3 (%12.5) | 0 | 0 | 3(%1.9) |
Others | 26 (%20.7) | 4 (%16.7) | 0 | 0 | 30(%18.9) |
Upfront ASCT | 39 (%31.0) | 7 (%29.2) | 1 (%14.3) | 0 | 47(%29.6) |
Follow Up Time (moths) | 39.3 (5–69) | 26.8 (4–54) | 6.6 (1–10) | — | |
Overall Survival (months) | 57.0 ± 9.6 | 32.0 ± 25.6 | 6 ± 4.2 | — | 50.0 ± 11.0 |
